Market Closed -
Japan Exchange
02:00:00 2024-04-26 EDT
|
5-day change
|
1st Jan Change
|
396
JPY
|
-2.94%
|
|
+1.54%
|
-25.28%
|
Fiscal Period: March |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
30,740
|
18,453
|
17,753
|
20,621
|
15,743
|
8,944
|
-
|
-
|
Enterprise Value (EV)
1 |
30,408
|
17,396
|
17,359
|
18,740
|
12,241
|
5,016
|
4,616
|
4,315
|
P/E ratio
|
54.2
x
|
38.2
x
|
32.9
x
|
26.1
x
|
15.7
x
|
29.1
x
|
29.1
x
|
22.4
x
|
Yield
|
0.88%
|
1.71%
|
1.78%
|
1.53%
|
2.01%
|
3.79%
|
3.79%
|
3.79%
|
Capitalization / Revenue
|
2.72
x
|
1.69
x
|
1.73
x
|
1.78
x
|
1.26
x
|
0.73
x
|
0.73
x
|
0.69
x
|
EV / Revenue
|
2.69
x
|
1.59
x
|
1.69
x
|
1.62
x
|
0.98
x
|
0.41
x
|
0.38
x
|
0.33
x
|
EV / EBITDA
|
18.3
x
|
11.9
x
|
19.8
x
|
12.3
x
|
6.97
x
|
4.37
x
|
4.48
x
|
3.51
x
|
EV / FCF
|
-31.2
x
|
38.6
x
|
-316
x
|
12.1
x
|
6.92
x
|
5.73
x
|
6.6
x
|
7.45
x
|
FCF Yield
|
-3.21%
|
2.59%
|
-0.32%
|
8.29%
|
14.5%
|
17.4%
|
15.1%
|
13.4%
|
Price to Book
|
5.85
x
|
3.46
x
|
3.11
x
|
3.15
x
|
2.08
x
|
1.18
x
|
1.18
x
|
1.14
x
|
Nbr of stocks (in thousands)
|
22,587
|
22,587
|
22,586
|
22,586
|
22,586
|
22,586
|
-
|
-
|
Reference price
2 |
1,361
|
817.0
|
786.0
|
913.0
|
697.0
|
396.0
|
396.0
|
396.0
|
Announcement Date
|
19-05-15
|
20-05-25
|
21-05-14
|
22-05-16
|
23-05-15
|
-
|
-
|
-
|
Fiscal Period: March |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
11,313
|
10,935
|
10,279
|
11,555
|
12,517
|
12,280
|
12,300
|
12,900
|
EBITDA
1 |
1,660
|
1,464
|
876.3
|
1,526
|
1,757
|
1,147
|
1,030
|
1,230
|
EBIT
1 |
1,212
|
1,005
|
453
|
1,086
|
1,257
|
717
|
600
|
800
|
Operating Margin
|
10.71%
|
9.19%
|
4.41%
|
9.4%
|
10.04%
|
5.84%
|
4.88%
|
6.2%
|
Earnings before Tax (EBT)
1 |
1,164
|
808
|
358
|
1,032
|
1,379
|
684
|
550
|
750
|
Net income
1 |
568
|
482
|
539
|
790.5
|
1,004
|
307
|
400
|
540
|
Net margin
|
5.02%
|
4.41%
|
5.24%
|
6.84%
|
8.02%
|
2.5%
|
3.25%
|
4.19%
|
EPS
2 |
25.09
|
21.38
|
23.91
|
35.00
|
44.47
|
13.60
|
13.60
|
17.70
|
Free Cash Flow
1 |
-976
|
451
|
-55
|
1,554
|
1,770
|
875
|
699
|
579
|
FCF margin
|
-8.63%
|
4.12%
|
-0.54%
|
13.45%
|
14.14%
|
7.13%
|
5.68%
|
4.49%
|
FCF Conversion (EBITDA)
|
-
|
30.8%
|
-
|
101.8%
|
100.76%
|
76.29%
|
67.86%
|
47.07%
|
FCF Conversion (Net income)
|
-
|
93.57%
|
-
|
196.59%
|
176.23%
|
285.02%
|
174.75%
|
107.22%
|
Dividend per Share
2 |
12.00
|
14.00
|
14.00
|
14.00
|
14.00
|
15.00
|
15.00
|
15.00
|
Announcement Date
|
19-05-15
|
20-05-25
|
21-05-14
|
22-05-16
|
23-05-15
|
-
|
-
|
-
|
Fiscal Period: March |
2020 S1
|
2021 S1
|
2022 Q2
|
2022 S1
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 S1
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 S1
|
2024 Q3
|
---|
Net sales
1 |
5,389
|
4,981
|
2,738
|
5,522
|
3,091
|
2,941
|
2,868
|
3,052
|
5,921
|
3,327
|
3,270
|
3,082
|
2,982
|
6,064
|
3,184
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
571
|
185
|
361.9
|
507.7
|
329
|
249.2
|
-26
|
400.2
|
373.4
|
367.3
|
516.4
|
112.1
|
309.2
|
421.2
|
220
|
Operating Margin
|
10.6%
|
3.71%
|
13.22%
|
9.19%
|
10.64%
|
8.47%
|
-0.91%
|
13.12%
|
6.31%
|
11.04%
|
15.79%
|
3.64%
|
10.37%
|
6.95%
|
6.91%
|
Earnings before Tax (EBT)
1 |
429
|
77
|
293.7
|
388
|
382
|
-
|
139
|
-
|
678
|
144
|
-
|
64
|
-
|
374
|
146
|
Net income
1 |
230
|
-13
|
185
|
252.6
|
272.3
|
265.6
|
76
|
391.9
|
468.8
|
110
|
426.8
|
3.532
|
175.4
|
178.9
|
74.64
|
Net margin
|
4.27%
|
-0.26%
|
6.76%
|
4.57%
|
8.81%
|
9.03%
|
2.65%
|
12.84%
|
7.92%
|
3.31%
|
13.05%
|
0.11%
|
5.88%
|
2.95%
|
2.34%
|
EPS
2 |
10.20
|
-0.6100
|
8.000
|
11.18
|
12.06
|
-
|
3.410
|
-
|
20.76
|
4.810
|
-
|
0.1600
|
-
|
7.920
|
3.310
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
19-11-14
|
20-11-13
|
21-11-12
|
21-11-12
|
22-02-14
|
22-05-16
|
22-08-12
|
22-11-14
|
22-11-14
|
23-02-14
|
23-05-15
|
23-08-14
|
23-11-14
|
23-11-14
|
24-02-14
|
Fiscal Period: March |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
332
|
1,057
|
394
|
1,881
|
3,502
|
3,928
|
4,328
|
4,629
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-976
|
451
|
-55
|
1,554
|
1,770
|
875
|
699
|
579
|
ROE (net income / shareholders' equity)
|
10.9%
|
9.1%
|
9.8%
|
12.9%
|
14.2%
|
4.1%
|
5.3%
|
7%
|
ROA (Net income/ Total Assets)
|
11.1%
|
6.67%
|
3.98%
|
7.63%
|
7.73%
|
4.6%
|
3.4%
|
4.5%
|
Assets
1 |
5,101
|
7,224
|
13,539
|
10,356
|
12,987
|
6,674
|
11,765
|
12,000
|
Book Value Per Share
2 |
232.0
|
236.0
|
253.0
|
290.0
|
336.0
|
334.0
|
337.0
|
346.0
|
Cash Flow per Share
|
30.90
|
29.40
|
32.70
|
43.20
|
52.60
|
-
|
-
|
-
|
Capex
1 |
180
|
741
|
78
|
77
|
69
|
100
|
100
|
100
|
Capex / Sales
|
1.59%
|
6.78%
|
0.76%
|
0.67%
|
0.55%
|
0.81%
|
0.81%
|
0.78%
|
Announcement Date
|
19-05-15
|
20-05-25
|
21-05-14
|
22-05-16
|
23-05-15
|
-
|
-
|
-
|
Average target price
500
JPY Spread / Average Target +26.26% Consensus |
1st Jan change
|
Capi.
|
---|
| -25.28% | 56.82M | | +1.51% | 42.75B | | +49.22% | 41.61B | | +8.57% | 41.34B | | -12.36% | 26.59B | | +8.92% | 25.49B | | -25.13% | 18.12B | | +29.17% | 12.24B | | -3.12% | 11.76B | | +6.35% | 11B |
Other Biotechnology & Medical Research
|